(+/-)-Codamine | 5977-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: (+/-)-Codamine
• 英文别名: dl-Codamine；1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol
• CAS: 5977-85-5
• 化学式: C₂₀H₂₅NO₄
• 分子量: 343.423
• InChiKey: OKORHWXYDBSYNO-UHFFFAOYSA-N

物化性质

• 沸点：
  483.4±45.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 熔点：
  126-127°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (+/-)-Codamine 以43%的产率得到
  参考文献：
  名称：

  HARA H.; HOSHINO O.; UMEZAWA B., HETEROCYCLES , 1975, 3, NO 2, 123-128

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 (+/-)-Codamine
  参考文献：
  名称：

  Spaeth; Epstein, Chemische Berichte, 1928, vol. 61, p. 340

  摘要：

  DOI：

文献信息

• Flow Conditions‐Controlled Divergent Oxidative Cyclization of Reticuline‐Type Alkaloids to Aporphine and Morphinandienone Natural Products
  作者：Bi Bali Judicaël Tra、Abollé Abollé、Vincent Coeffard、François‐Xavier Felpin

  DOI：10.1002/ejoc.202200301

  日期：2022.6.13

  We describe a divergent continuous-flow approach for the biomimetic oxidative cyclization of reticuline-type alkaloids to aporphine and morphinandienone natural products using hypervalent iodine compounds.

  我们描述了一种使用高价碘化合物将网状生物碱仿生氧化环化为阿吗啡和吗啡二烯酮天然产物的发散连续流动方法。
• Process for production of vinyl chloride polymer
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：EP0172427A2

  公开（公告）日：1986-02-26

  This process is a process for production of a vinyl chloride polymer by suspension polymerization or emulsion polymerization of vinyl chloride monomer or a mixture of vinyl chloride monomer with a vinyl monomer copolymerizable with said vinyl chloride monomer in an aqueous medium, characterized in that the polymerization is carried out in a polymerizer, the inner wall surface and portions of the auxiliary equipment thereof which may come into contact with the monomer during polymerization being previously coated with a scaling preventive comprising at least one selected from dyes, pigments and aromatic or heterocyclic compounds having at least 5 conjugated π bonds, while controlling the chloride ion concentration in the reaction mixture to not higher than 100 ppm. According to said process, scaling onto the inner wall surface of a polymerizer, etc. during polymerization can be prevented effectively and surely.

  该工艺是通过氯乙烯单体或氯乙烯单体与可与所述氯乙烯单体共聚的乙烯基单体混合物在水介质中进行悬浮聚合或乳液聚合来生产氯乙烯聚合物的工艺，其特征在于聚合是在聚合器中进行的、内壁表面及其辅助设备中可能在聚合过程中与单体接触的部分事先涂上一层防垢剂，该防垢剂至少包括一种选自染料、颜料和至少有 5 个共轭 π 键的芳香族或杂环化合物的防垢剂，同时控制反应混合物中的氯离子浓度不高于 100 ppm。根据上述工艺，可有效、可靠地防止聚合过程中聚合器等内壁表面结垢。
• Use of palonosetron for treating post-operative nausea and vomiting
  申请人：Helsinn Healthcare S.A.

  公开号：EP2258367A2

  公开（公告）日：2010-12-08

  Methods are provided to treat post-operative nausea and vomiting, as well as emesis generally, with 5-HT3 receptor antagonists. In particular, the invention discloses methods for reducing post-operative nausea and vomiting and other emetic events with palonosetron.

  本发明提供了用 5-HT3 受体拮抗剂治疗术后恶心和呕吐以及一般催吐的方法。特别是，本发明公开了使用帕洛诺司琼减少术后恶心和呕吐以及其他催吐事件的方法。
• Compositions and methods for making (R)-Reticuline and precursors thereof
  申请人：Epimeron Inc.

  公开号：US10190141B2

  公开（公告）日：2019-01-29

  Methods that may be used for the manufacture of the chemical compound (R)-Reticuline and synthesis precursors thereof. Compositions useful for the synthesis (R)-Reticuline and synthesis precursors are also provided.

  可用于制造 (R)-Reticuline 化合物及其合成前体的方法。此外，还提供了用于合成 (R)-Reticuline 及其合成前体的组合物。
• Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
  申请人：Thottathil John K.

  公开号：US10449190B2

  公开（公告）日：2019-10-22

  The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明描述了由一种配体组成的药物化合物和组合物，该配体与阿片类物质相连接的方式可大大降低或阻止阿片类物质滥用、成瘾、非法和违法使用以及用药过量的可能性。以适当剂量给药时，药物组合物可提供与母体活性剂类似的治疗活性。